Skip to main content

Home/ MaRS/ Group items tagged Aggregate Therapeutics Inc

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Assunta Krehl

Aggregate Therapeutics to play a key role in commercializing stem cell discoveries - 0 views

www.marsdd.com/...MaRS-in-the-Media.html

Stem Cell Aggregate Therapeutics Inc MaRS Ilse Treurnicht

shared by Assunta Krehl on 10 Aug 09 - No Cached
  • Assunta Krehl on 10 Aug 09
     
    Biotechnologies au Canada: l'exemple de l'Ontario in Industrie Pharmaceutique, May 22, 2009 mentions that MaRS Discovery District is an Innovation Centre and mentions how it helps entrepreneurs to commercialize their research.
  • ...6 more comments...
  • Assunta Krehl on 13 Aug 09
     
    Cluster Growth Through Collaboration article in Ciencia Conocimiento Tecnologia, March 20, 2009 mentions about the MaRS story, MaRS' mission and programs and resources offered to entrepreneurs.
  • Assunta Krehl on 13 Aug 09
     
    Cluster Growth Through Collaboration article in Ciencia Conocimiento Tecnologia, March 20, 2009 mentions about the MaRS story, MaRS' mission and programs and resources offered to entrepreneurs.
  • Assunta Krehl on 13 Aug 09
     
    Cluster Growth Through Collaboration article in Ciencia Conocimiento Tecnologia, March 20, 2009 mentions about the MaRS story, MaRS' mission and programs and resources offered to entrepreneurs.
  • Assunta Krehl on 13 Aug 09
     
    From Mars to MaRS - Taking engineering innovation to the world from Globe and Mail Supplement. Article features MaRS and Krista Jones states "MaRS helps emerging start-up and entrepreneurial companies commercialize promising innovations." Jones states that "40% of MaRS Clients are engineering-based companies."
  • Assunta Krehl on 24 Aug 09
     
    Sowing the Seeds, Toronto Board of Trade member magazine, Dec 1, 2007. Skymeter Corp is working on a GPS technology for toll collection, parking management, and pay-as-you-drive insurance. The article talks about how entrepreneurs go about raising capital.
  • Assunta Krehl on 27 Aug 09
     
    As stated in Burrill Canadian Biotech News, "MaRS Discovery Distruict and Canadian Stem Cell Network have entered into a partnership agreement to pursue long-term publc oro private financing for the translational development activities currently being undertaken by Aggregate Therapeutics."
  • Assunta Krehl on 27 Aug 09
     
    As stated in Burrill Canadian Biotech News, "MaRS Discovery District and Canadian Stem Cell Network have entered into a partnership agreement to pursue long-term public or private financing for the translational development activities currently being undertaken by Aggregate Therapeutics."
  • Assunta Krehl on 27 Aug 09
     
    As stated in Burrill Canadian Biotech News, "MaRS Discovery District and Canadian Stem Cell Network have entered into a partnership agreement to pursue long-term public or private financing for the translational development activities currently being undertaken by Aggregate Therapeutics."
Assunta Krehl

Stem Cell Network teaming with MaRS to accelerate commercialization efforts - Research ... - 0 views

findarticles.com/...ai_n23654095

Aggregat Therapeutics Inc stem cell MaRS

shared by Assunta Krehl on 24 Aug 09 - Cached
  • The Stem Cell Network (SCN) has entered into a collaborative agreement with the MaRS Discovery District to transfer control of its nascent spin-off commercialization arm, Aggregate Therapeutics Inc (ATI). The agreement will see MaRS take immediate management responsibility for ATI, seek funding to operationalize the company and accelerate efforts to commercialize stem cell and regenerative medical research
  • Assunta Krehl on 24 Aug 09
     
    The Stem Cell Network (SCN) has entered into a collaborative agreement with the MaRS Discovery District to transfer control of its nascent spin-off commercialization arm, Aggregate Therapeutics Inc (ATI). The agreement will see MaRS take immediate management responsibility for ATI, seek funding to operationalize the company and accelerate efforts to commercialize stem cell and regenerative medical research
  • Assunta Krehl on 24 Aug 09
     
    Research Money states "The Stem Cell Network (SCN) has entered into a collaborative agreement with the MaRS Discovery District to transfer control of its nascent spin-off commercialization arm, Aggregate Therapeutics Inc (ATI). The agreement will see MaRS take immediate management responsibility for ATI, seek funding to operationalize the company and accelerate efforts to commercialize stem cell and regenerative medical research." April 24, 2007
Assunta Krehl

Toronto's $25 million commercialization "engine" celebrates the appointment of its Boar... - 0 views

www.marsdd.com/...ard-of-directors-02062009.html

MaRS Innovation Ilse Treurnicht John Evans Ron Close The Hospital for Sick Children MaRS

shared by Assunta Krehl on 14 Aug 09 - No Cached
  • MaRS Innovation is honoured to announce its permanent Board of Directors, who brings together a remarkable and broad set of experiences and networks to support the development of this dynamic partnership of Toronto research institutions.  Designed to enhance the commercial output of Toronto’s world-leading research cluster, MaRS Innovation is positioned to make a significant contribution to Canada’s innovation economy and the quality of life for Canadians and others around the world.
  • upported by the Government of Canada through the Centres of Excellence in Research and Commercialization (CECR) program, and its member institutions, MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs. The newly appointed Board of Directors, which includes academic and business leaders from across Canada and the United States, has the targeted expertise to guide MaRS Innovation to deliver on this critical mission.   MaRS Innovation represents a unique collaborative model, which aggregates the exceptional discovery pipeline of 14 leading Toronto academic institutions to build a diversified portfolio of assets, and harness the economic and job creation potential of the best opportunities for Toronto, Ontario and Canada.
  • “MaRS Innovation is privileged to announce a Board of Directors of this caliber and breadth of skill,” said Mary Jo Haddad, Chair of the MaRS Innovation Board and President and CEO of The Hospital for Sick Children. “The collective experience and guidance of these individuals will be critical to developing a collaborative, integrated and agile approach to this transformational organization that will move Canada into its next phase of economic development.”
  • ...2 more annotations...
  • W. Geoffrey Beattie – Deputy Chairman & President, Woodbridge Company Limited, Thomson Reuters Corporation, Toronto Christopher C. Capelli – Vice President, Technology Based Ventures, Office of Technology Commercialization, University of Texas, M.D. Anderson Cancer Center, Houston, TX Ron Close – Information technology entrepreneur, Entrepreneur-in-Residence, MaRS, and Executive Entrepreneur-in-Residence, The Richard Ivey School of Business, The University of Western Ontario, London, ON Nicholas Darby – Formerly Director of Physical Sciences, Corporate Venture Capital, Dow Chemical Company, President, Darby & Associates Consulting LLC, Midland, MI  Mary Jo Haddad – President & CEO, The Hospital for Sick Children, Toronto Jacqueline H.R. Le Saux – Former General Counsel, North America and Corporate Secretary, Patheon, Inc., Toronto David A. Leslie - Chair, Sunnybrook Health Sciences Centre, and Former Chairman & CEO, Ernst & Young, Toronto Michael H. May – President & CEO, Rimon Therapeutics, Toronto Chandra J. Panchal – Founder, President & CEO, Axcelon Biopolymers Corp., Dollard-des-Ormeaux, QC Ilse Treurnicht – CEO, MaRS Discovery District, Toronto Donald A. Wright – President & CEO, The Winnington Capital Group Inc., Toronto
  • MaRS Innovation serves as a business accelerator platform with a single point of entry for industry partners and investors.  It will increase the scale, scope and viability of IP offerings, and the quantity and quality of deal flow from partner institutions.  MaRS Innovation will also facilitate strategic research collaborations with industry partners, strengthen the innovation capacity of Canadian industry through adoption of new technologies from its member institutions, and launch a new generation of robust, high-growth Canadian companies that will become global market leaders.   The quality of the combined discovery pipeline will catalyze and attract sources of risk capital for translational research, market validation, company formation and growth.  “MaRS Innovation represents a unique and timely platform to contribute in a meaningful way to Canada’s knowledge economy, leveraging Toronto’s remarkable research excellence.  The vision and serious commitment of its members to work together to transform our commercialization results, and the support of the Federal Government, made this possible.  The announcement of this outstanding group of leaders to the Board of Directors for MaRS Innovation is an exciting step forward,” said Ilse Treurnicht, MaRS CEO and interim Managing Director of MaRS Innovation.
  • Assunta Krehl on 14 Aug 09
     
    MaRS Innovation announced its permanent Board of Directors. MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs.
  • Assunta Krehl on 14 Aug 09
     
    MaRS Innovation announced its permanent Board of Directors. MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs. Feb 6, 2009
1 - 3 of 3
Showing 20▼ items per page